p53 expression in node-positive breast cancer patients: Results from the cancer and leukemia group B 9344 trial (159905)

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 5170-5178

  Lara, Jonathan F ^a   Thor, Ann D ^b   Dressler, Lynn G ^c   Broadwater, Gloria ^e   Bleiweiss, Ira J ^f   Edgerton, Susan ^b   Cowan, David ^d   Goldstein, Lori J ^h   Martino, Silvana ⁱ   Ingle, James N ^j   Henderson, I Craig ^k   Norton, Larry ^g   Winer, Eric P ^l   Hudis, Clifford A ^g   Ellis, Matthew J ^m   Berry, Donald A ⁿ   Hayes, Daniel F ^o  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ Angeles Clinic and Research Institute ^*  (United States)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RELAPSE FREE SURVIVAL;

ADULT; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79961000358     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0484     Document Type: Article

References (35)

1. Rolland P, Spendlove I, Madjid Z, Rakha EA, Patel P, Ellis IO, et al. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 2007;120:1131-7.
2. Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, et al. p53 accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 2006;8:R48.
3. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10. (Pubitemid 24359290)
4. Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulous A, et al. Prognostic significance of the coexpression of p53 and c-erbB-2 proteins in breast cancer. J Pathol 1996;179:31-8. (Pubitemid 26180083)
5. Andersson J, Larsson L, Klaar S, Holmberg L, Nillson J, Inganass M, et al. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant therapy. Ann Oncol 2005;16:743-8. (Pubitemid 40767094)
6. Dai M-S, Sun X-X, Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle. Mol Cell Biol 2008;28:4365-76. (Pubitemid 351904958)
7. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, et al. Coexistence of Her-2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004;6:R24-30.
8. Gülben K, Berberoǧlu U, Cengiz A, Altinyollar H. Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer. World J Surg 2007;31:1724-30. (Pubitemid 47283196)
9. Wiltschke C, Kindas-Muegge I, Steininger A, Reiner A, Preis PN. Coexpression of Her-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 1994;120:737-42. (Pubitemid 24361969)
10. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L, et al. p53 in node-negative breast cancer: an immunohistochemical study of epidemiologic risk factors, histologic features and prognosis. J Clin Oncol 1995;13:821-30.
11. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47. (Pubitemid 24322246)
12. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. Prognostic significance of p53, Bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 2004;198:83-90. (Pubitemid 38201092)
13. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992;84:845-55.
14. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Aisner J. TP53 is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000;39:327-33. (Pubitemid 30643080)
15. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, et al. p53 and Bcl-2 expression correlates with clinical outcome in series of node-positive breast cancer patients. J Clin Oncol 1996;14:1604-10. (Pubitemid 26134219)
16. Krocombining double acute accentger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006;12:159-68.
17. Silvestrini R, Veneroni S, Benini E, Daidone MG, Luisi A, Leutner M, et al. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997;89:639-44.
18. Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant therapy. Ann Oncol 2006;17:1504-11. (Pubitemid 44542035)
19. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346-60. (Pubitemid 28439959)
20. Aas T, Borrensen A-L, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4. (Pubitemid 26225099)
21. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-6. (Pubitemid 30064975)
22. Rahko E, Blanco G, Soini Y, Bloigu R, Jukkola A. A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 2003;39:447-53. (Pubitemid 36173688)
23. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, DeCremoux P, Bernoux A, et al. No significant predictive value of c-ErbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998;79:27-33. (Pubitemid 28157722)
24. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendation for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312. (Pubitemid 350232263)
25. Henry L, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast cancer. Oncologist 2006;11:541-52. (Pubitemid 43967610)
26. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
27. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-11. (Pubitemid 28407086)
28. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83. (Pubitemid 46594124)
29. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. Her-2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506. (Pubitemid 47572635)
30. von Minckwitz G, Sinn H-P, Raab G, Loible S, Blohmer JU, Eidtmann H, et al. Clinical response after two cycles compared to Her-2, Ki-67, p53 and Bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008;10:R30.
31. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
32. Conway K, Edminston S, Cui L, Drouin SS, Pang J, He M, et al. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. Cancer Res 2002;62:1987-95. (Pubitemid 34408442)
33. Rahman-Robick R, Hellman U, Becker S, Bader FG, Auer G, Wiman KG, et al. Proteomic identification of p53-dependent protein phosphorylation. Oncogene 2008;27:4854-9.
34. Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, et al. p53 expression in tumor stromal fibroblasts forming and not forming fibrotic foci in invasive ductal carcinoma of the breast. Mod Pathol 2010;23:662-72.
35. Teusch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.